MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova announced the completion of last patient last visit (LPLV) in its Phase 2 trial MN-001-NATG-202. The study evaluates MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD associated with type 2 diabetes.
Key figures
- Drug Name
- MN-001 (tipelukast)
- Phase Of Trial
- Phase 2
- Dosage
- 500 mg/day
- Duration
- 24 weeks
- Data readout
- Q3 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.